{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T15:58:23Z","timestamp":1774367903521,"version":"3.50.1"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1038\/s41409-024-02505-x","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T04:05:16Z","timestamp":1737518716000},"page":"538-540","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["T cell redirection as a new standard of care for relapsed multiple myeloma: impact on inpatient capacity, financial burden and infrastructural requirements in Germany"],"prefix":"10.1038","volume":"60","author":[{"given":"P.","family":"Ahmadi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Alsdorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9248-588X","authenticated-orcid":false,"given":"L.","family":"Leypoldt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Kosch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Schaefers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Gagelmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6297-1847","authenticated-orcid":false,"given":"F.","family":"Ayuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Kron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9422-6614","authenticated-orcid":false,"given":"K.","family":"Weisel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,22]]},"reference":[{"key":"2505_CR1","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/ejh.13840","volume":"109","author":"CY Soekojo","year":"2022","unstructured":"Soekojo CY, Chng WJ. Treatment horizon in multiple myeloma. Eur J Haematol. 2022;109:425\u201340.","journal-title":"Eur J Haematol"},{"key":"2505_CR2","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","volume":"36","author":"M Mateos","year":"2022","unstructured":"Mateos M, Weisel K, De Stefano V, Goldschmidt H, Delforge M, Mohty, et al. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma. Leukemia. 2022;36:1371\u20136. https:\/\/doi.org\/10.1038\/s41375-022-01531-2","journal-title":"Leukemia"},{"key":"2505_CR3","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","volume":"33","author":"UH Gandhi","year":"2019","unstructured":"Gandhi UH, Cornell RF, Lakshman A, Gahvari ZJ, McGehee E, Jagosky MH, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33:2266\u201375. https:\/\/doi.org\/10.1038\/s41375-019-0435-7","journal-title":"Leukemia"},{"key":"2505_CR4","unstructured":"Brystol-Myers Squibb Pharma. FACHINFORMATION\/ZUSAMMENFASSUNG DER MERKMALE DES ARZNEIMITTELS ABECMA\u00ae 260 \u2013 500 \u00d7 106 Zellen Infusionsdispersion. 2024. http:\/\/fi.b-ms.de\/abecma"},{"key":"2505_CR5","doi-asserted-by":"publisher","first-page":"8503","DOI":"10.1200\/JCO.2020.38.15_suppl.8503","volume":"38","author":"NC Munshi","year":"2020","unstructured":"Munshi NC, Anderson LD Jr, Shah N, Jagannath S, Berdeja JG, Lonial S, et al. Idecabtagene vicleucel (ide-cel; bb2121), a BCMA-targeted CAR T-cell therapy, in patients with relapsed and refractory multiple myeloma (RRMM): Initial KarMMa results. J Clin Oncol. 2020;38:8503.","journal-title":"J Clin Oncol"},{"key":"2505_CR6","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384:705\u201316.","journal-title":"N Engl J Med"},{"key":"2505_CR7","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.2217\/fon-2023-0954","volume":"20","author":"P Rodriguez-Otero","year":"2024","unstructured":"Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, et al. Plain Language Summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myeloma. Future Oncol. 2024;20:1221\u201335.","journal-title":"Future Oncol"},{"key":"2505_CR8","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","volume":"388","author":"P Rodriguez-Otero","year":"2023","unstructured":"Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, et al. Ide-CEL or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med. 2023;388:1002\u201314.","journal-title":"N Engl J Med"},{"key":"2505_CR9","unstructured":"Janssen-Cilag International. FACHINFORMATION CARVYKTI\u00ae Infusionsdispersion. 2024. https:\/\/static.janssen-emea.com\/sites\/default\/files\/Germany\/SMPC\/DE-PL-0070.pdf"},{"key":"2505_CR10","unstructured":"Gemeinsamer Bundesausschuss (GBA). Dossier zur Nutzenbewertung gem\u00e4\u00df \u00a7 35a SGB V, Pomalidomid (IMNOVID\u00ae), Modul 1, 26-27. 2019. https:\/\/www.g-ba.de\/downloads\/92-975-3113\/2019-06-06_Modul1_Pomalidomid.pdf"},{"key":"2505_CR11","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1182\/blood.2023022432","volume":"143","author":"JL Crombie","year":"2024","unstructured":"Crombie JL, Graff T, Falchi L, Karimi YH, Bannerji R, Nastoupil L, et al. Consensus recommendations on the management of toxicity associated with CD3\u00d7CD20 bispecific antibody therapy. Blood. 2024;143:1565\u201375. https:\/\/doi.org\/10.1182\/blood.2023022432","journal-title":"Blood"},{"key":"2505_CR12","doi-asserted-by":"publisher","unstructured":"Scott SA, Marin EM, Maples KT, Joseph NS, Hofmeister CC, Gupta VA, et al. Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: a single-center experience. Blood Cancer Journal, 13. 2023. https:\/\/doi.org\/10.1038\/s41408-023-00963-y","DOI":"10.1038\/s41408-023-00963-y"},{"key":"2505_CR13","doi-asserted-by":"publisher","first-page":"e13575","DOI":"10.1200\/jco.2024.42.16_suppl.e13575","volume":"42","author":"WB Donnellan","year":"2024","unstructured":"Donnellan WB, Abbas J, Berdeja JG, Byrne M, Chandler JC, Cassoli L, et al. Use of bispecific antibodies (BsAbs) in community practices: Key attributes to develop logistics and workflow for management of cytokine release syndrome (CRS). J Clin Oncol. 2024;42:e13575. https:\/\/doi.org\/10.1200\/jco.2024.42.16_suppl.e13575","journal-title":"J Clin Oncol"},{"key":"2505_CR14","doi-asserted-by":"publisher","first-page":"5746","DOI":"10.3390\/cancers15245746","volume":"15","author":"DK Hansen","year":"2023","unstructured":"Hansen DK, Liu Y, Ranjan S, Bhandari H, Potluri R, McFarland L, et al. The impact of outpatient versus inpatient administration of CAR-T therapies on clinical, economic, and humanistic outcomes in patients with hematological cancer: a systematic literature review. Cancers. 2023;15:5746. https:\/\/doi.org\/10.3390\/cancers15245746","journal-title":"Cancers"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-024-02505-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-024-02505-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-024-02505-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T05:55:42Z","timestamp":1743832542000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-024-02505-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,22]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["2505"],"URL":"https:\/\/doi.org\/10.1038\/s41409-024-02505-x","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,22]]},"assertion":[{"value":"6 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"PA: no competing interests. WA: Travel expenses\/congress support: Immatics, BioNTech, Janssen. Research funding (Instiution): Affimed, BioNTech. Advisory Role and Honoraria: Immatics, GSK, Astellas, AstraZeneca,Janssen. LL: Advisory Role and Honoraria: Adaptive, AbbVie, Bristol Myers Squibb\/Celgene, GlaxoSmithKline, Janssen-Cilag, Pfizer, Sanofi. Research Funding: AbbVie, GlaxoSmithKline. Travel Support: Oncopeptides, Sanofi. RK: travel grants by Amgen. CS: consultancy for Acus Health, Astra Zeneca, Janssen-Cilag, Menarini Stemline, Pfizer; honoraria from Abbvie, Astra Zeneca, Janssen-Cilag; other (travel expenses\/congress support): Acus Health, Astra Zeneca, Bristol Myers Squibb, Menarini Stemline, oncopeptides, Sanofi. NG: Advisory Role and Honoraria: Bristol Myers Squibb\/Celgene, Stemline, Pfizer, Kite\/Gilead, Janssen-Cilag\/J&J. FA: Honoraria: Medac, Takeda, Kite\/Gilead, BMS\/Celgene, Janssen, Miltenyi Biomedicine, Novartis, AbbVie, Mallinkrodt\/Therakos. Research funding: Mallinckrodt\/Therakos. FK: employed by VITIS GmbH and holds a professorship at FOM University of Applied Sciences for Economics and Management. KW: Research Grant: Abbvie, Amgen, BMS\/Celgene, GSK, Janssen, Sanofi (to the Institution) Honoraria: Abbvie, Amgen, Adaptive Biotech, Astra Zeneca, Beigene, BMS, Celgene, Janssen, GSK, Karyopharm, Menarini, Novartis, Oncopeptides, Pfizer, Roche, Sanofi, Stemline, Takeda Adisory Board: Abbvie, Amgen, Adaptive Biotech, Beigene, BMS, Celgene, Janssen, GSK, Karyopharm, Menarini, Novartis, Oncopeptides, Pfizer, Regeneron, Roche, Sanofi, Takeda.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}